Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lévy, D.
Right arrow Articles by Gompel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lévy, D.
Right arrow Articles by Gompel, A.
Clinical Cancer Research Vol. 10, 3124-3130, May 1, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Death-Associated Protein Kinase Loss of Expression Is a New Marker for Breast Cancer Prognosis

Delphine Lévy1, Geneviève Plu-Bureau1, Yves Decroix1, Danielle Hugol2, William Rostène3, Adi Kimchi4 and Anne Gompel1,3

1 Unité de Gynécologie Endocrinienne and 2 Département d’Anatomo-Pathologie, Hôpital Hôtel Dieu, Paris, France; 3 Inserm U 339, Hôpital Saint-Antoine, Paris, France; and 4 Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

Purpose: Death-associated protein (DAP)-kinase is a new Ser/Thr kinase involved in cell apoptosis and tumor suppression, the expression of which has been correlated to invasive potential and metastasis in several human neoplastic tissues. We analyzed the level of DAP-kinase expression in breast cancer specimens and its correlation with survival.

Experimental Design: One hundred twenty-eight breast cancer specimens were analyzed by immunohistochemistry. Patient records were studied retrospectively for demographic characteristics, clinical data, hormonal treatment, outcome, and survival. DAP-kinase protein expression was also studied in normal breast cells primary cultures under estrogen and antiestrogen treatment.

Results: Among the 128 patients, 30 showed a DAP-kinase staining <= 20%, whereas 98 had a staining over 20%. Mean follow-up time was 62 months. The association between tumor Scarff-Bloom and Richardson grade (P = 0.009), estrogen receptor and progesterone receptor expression (P = 0.002 and 0.001, respectively), tumor size (P = 0.05), Bcl-2 expression (P = 0.004), and DAP-kinase immunostaining in the ductal carcinoma group was highly significant. Overall (64 months) and disease-free (63 months) survival in the high DAP-kinase expression group were significantly longer compared with the women whose tumors showed a loss of DAP-kinase expression (51 and 43 months, respectively). DAP-kinase protein was strongly expressed in normal breast tissue and in human breast epithelial cells primary cultures. Estradiol decreased DAP-kinase expression in these cells, arguing for hormonal regulation of the protein.

Conclusions: Loss of DAP-kinase expression negatively correlates to survival and positively correlates to the probability of recurrence in a very significant manner. DAP-kinase thus constitutes a novel and independent prognosis marker for breast cancer.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Stevens, Y. Lin, M. Sanchez, E. Amin, E. Copson, H. White, V. Durston, D. M. Eccles, and T. Hupp
A Germ Line Mutation in the Death Domain of DAPK-1 Inactivates ERK-induced Apoptosis
J. Biol. Chem., May 4, 2007; 282(18): 13791 - 13803.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
Z. Yang, L. E. Harris, D. E. Palmer-Toy, and W. S. Hancock
Multilectin Affinity Chromatography for Characterization of Multiple Glycoprotein Biomarker Candidates in Serum from Breast Cancer Patients
Clin. Chem., October 1, 2006; 52(10): 1897 - 1905.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.